Pricing

AC Immune SA (ACIU)

followers ยท
Sector: HEALTH CARE
Industry: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
CEO: Andrea Pfeifer
Employees: 140
Web site: acimmune.com
EPFL INNOVATION PARK, BUILDING B, 1015 LAUSANNE, V8, 00000
41 21 345 91 21
All 13F Filers Prior Change Hedge Funds 1 Prior Change
AC Immune SA discovers, designs, and develops medicines and diagnostic products. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease. It is also developing ACI-24, an anti-Abeta vaccine candidate, as well as completed Phase Ib clinical study for Down syndrome. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases.
Please log in first to see chart
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available